{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:44:29Z","timestamp":1791927869016,"version":"4.3.4"},"reference-count":102,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.semnephrol.2026.151689","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:04:33Z","timestamp":1782878673000},"page":"151689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current Options for Kidney Protection: Are Renin\u2013Angiotensin System Inhibitors Still Relevant?"],"prefix":"10.1016","volume":"46","author":[{"given":"Waichi","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2026.151689_bib0001","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","article-title":"Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","year":"2025","journal-title":"Lancet."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0002","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1007\/s00467-007-0524-0","article-title":"Mechanisms of progression of chronic kidney disease","volume":"22","author":"Fogo","year":"2007","journal-title":"Pediatr Nephrol."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0003","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1172\/JCI72267","article-title":"Cellular and molecular mechanisms in kidney fibrosis","volume":"124","author":"Duffield","year":"2014","journal-title":"J Clin Invest."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0004","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41572-024-00589-9","article-title":"Chronic kidney disease","volume":"11","author":"Romagnani","year":"2025","journal-title":"Nat Rev Dis Primers."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0005","first-page":"F85","article-title":"Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation","volume":"241","author":"Hostetter","year":"1981","journal-title":"Am J Physiol."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0006","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1046\/j.1523-1755.2000.00031.x","article-title":"Renoprotective benefits of RAS inhibition: from experimental models to clinical trials","volume":"57","author":"Taal","year":"2000","journal-title":"Kidney Int."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0007","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0008","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0009","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0010","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0011","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.semnephrol.2003.11.004","article-title":"Impact of renin angiotensin system blockade on renal function in health and disease: an end or a beginning?","volume":"24","author":"Abdi","year":"2004","journal-title":"Semin Nephrol."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0012","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1111\/j.1600-6143.2010.03290.x","article-title":"Chronic humoral rejection of human kidney allografts is associated with MMP-2 accumulation in podocytes and its release in the urine","volume":"10","author":"Wong","year":"2010","journal-title":"Am J Transplant."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0013","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0014","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting\u2013enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","volume":"355","year":"2000","journal-title":"Lancet."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0016","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0017","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0018","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0019","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0020","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","year":"1991","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0021","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0022","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack","volume":"358","year":"2001","journal-title":"Lancet."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0023","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0024","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","article-title":"A comparison of outcomes with angiotensin-converting\u2013enzyme inhibitors and diuretics for hypertension in the elderly","volume":"348","author":"Wing","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0025","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","article-title":"Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES)","volume":"36","author":"Schrader","year":"2005","journal-title":"Stroke."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0026","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0140-6736(08)61412-9","article-title":"Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials","volume":"372","author":"Chaturvedi","year":"2008","journal-title":"Lancet."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0027","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(08)61411-7","article-title":"Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial","volume":"372","author":"Sj\u00f8lie","year":"2008","journal-title":"Lancet."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0028","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1093\/eurheartj\/eht334","article-title":"Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial","volume":"34","author":"Groenink","year":"2013","journal-title":"Eur Heart J."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0029","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.kint.2019.12.015","article-title":"A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome","volume":"97","author":"Gross","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41581-021-00526-z","article-title":"Improving outcomes in glomerular disease","volume":"18","author":"Kronbichler","year":"2022","journal-title":"Nat Rev Nephrol."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0031","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/ajhp\/zxac139","article-title":"Immune globulin therapy and kidney disease: overview and screening, monitoring, and management recommendations","volume":"79","author":"Kobayashi","year":"2022","journal-title":"Am J Health Syst Pharm."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0032","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0033","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fern\u00e1ndez-Ju\u00e1rez","year":"2021","journal-title":"Kidney Int."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0034","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1046\/j.1523-1755.1999.00778.x","article-title":"A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis","volume":"56","author":"Cattran","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0035","article-title":"Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS One."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0036","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0037","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0038","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0039","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0040","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2026.151689_bib0041","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0042","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0043","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2016.06.009","article-title":"Plasmapheresis for the treatment of kidney diseases","volume":"90","author":"Clark","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0044","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0045","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0046","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0047","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0048","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0049","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0050","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0051","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0052","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0053","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0054","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0055","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.297.15.joc70035","article-title":"Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial","volume":"297","author":"Alexander","year":"2007","journal-title":"JAMA."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0056","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0057","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibitors: the 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100855","article-title":"Ravulizumab in atypical hemolytic uremic syndrome: an analysis of 2-year efficacy and safety outcomes in 2 phase 3 trials","volume":"6","author":"Dixon","year":"2024","journal-title":"Kidney Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0059","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0060","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0061","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0062","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1056\/NEJMoa2501510","article-title":"Trial of pegcetacoplan in C3 glomerulopathy and immune-complex MPGN","volume":"393","author":"Fakhouri","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0063","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0064","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease: a randomized double-blind trial","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0065","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0066","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0067","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0068","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0069","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0070","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","article-title":"Sparsentan versus irbesartan in focal segmental glomerulosclerosis","volume":"389","author":"Rheault","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0071","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa2308695","article-title":"Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria","volume":"390","author":"Peffault de Latour","year":"2024","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0072","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0073","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(25)01148-1","article-title":"Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study","volume":"406","author":"Kavanagh","year":"2025","journal-title":"Lancet."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0074","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0075","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0076","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1016\/j.ekir.2025.09.044","article-title":"DMX-200 in patients with primary focal segmental glomerulosclerosis: results of the phase 2 ACTION2 trial","volume":"10","author":"Heerspink","year":"2025","journal-title":"Kidney Int Rep."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0077","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae268","article-title":"Cystatin C vs creatinine eGFR in advanced chronic kidney disease: an analysis of the STOP-ACEi trial","volume":"17","author":"Spencer","year":"2024","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0078","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1681\/ASN.2010090967","article-title":"Anti-phospholipase A2 receptor antibody in membranous nephropathy","volume":"22","author":"Qin","year":"2011","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0079","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.semnephrol.2021.09.003","article-title":"Plasma and urine biomarkers of CKD: a review of findings in the CKiD study","volume":"41","author":"Sandokji","year":"2021","journal-title":"Semin Nephrol."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0080","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa2202396","article-title":"Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants","volume":"388","author":"Egbuna","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2026.151689_bib0081","unstructured":"AstraZeneca. Dose-ranging safety, tolerability, and efficacy study of AZD2373 in participants with APOL1-mediated kidney disease (APPRECIATE). ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06824987."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0082","unstructured":"Maze Therapeutics. A phase 2 study of MZE829 in adults with APOL1 kidney disease (NCT06830629). ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06830629"},{"key":"10.1016\/j.semnephrol.2026.151689_bib0083","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0084","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0085","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamacardio.2025.4491","article-title":"Rationale, design, and baseline clinical characteristics of the ziltivekimab cardiovascular outcomes trial: interleukin-6 inhibition and atherosclerotic event rate reduction","volume":"11","author":"Ridker","year":"2026","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0086","series-title":"Presented at: European Society of Cardiology Congress","article-title":"A multicenter, randomized, double-blind, placebo-controlled phase 2 trial of pacibekitug in patients with elevated hs-CRP and chronic kidney disease: TRANQUILITY 90-day results","author":"Pergola","year":"2025"},{"key":"10.1016\/j.semnephrol.2026.151689_bib0087","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMoa2510198","article-title":"A phase 3 trial of atacicept in patients with IgA nephropathy","volume":"394","author":"Lafayette","year":"2026","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0088","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.kint.2017.10.020","article-title":"Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney disease","volume":"93","author":"Pruijm","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0089","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","article-title":"High-performance medicine: the convergence of human and artificial intelligence","volume":"25","author":"Topol","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.semnephrol.2026.151689_bib0090","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.3390\/bioengineering12101069","article-title":"Artificial intelligence in nephrology: from early detection to clinical management of kidney diseases","volume":"12","author":"Nicosia","year":"2025","journal-title":"Bioengineering (Basel)."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0091","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2026.108104","article-title":"Gene modification: exploring the potential in treating kidney diseases","volume":"224","author":"Ekperikpe","year":"2026","journal-title":"Pharmacol Res."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0092","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00467-021-05352-w","article-title":"The potential of RNA-based therapy for kidney diseases","volume":"38","author":"Bondue","year":"2023","journal-title":"Pediatr Nephrol."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0093","doi-asserted-by":"crossref","first-page":"F695","DOI":"10.1152\/ajprenal.00166.2023","article-title":"Navigating the kidney organoid: insights into assessment and enhancement of nephron function","volume":"325","author":"Tabibzadeh","year":"2023","journal-title":"Am J Physiol Renal Physiol."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0094","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ajt.2022.11.022","article-title":"Renin-angiotensin-aldosterone system function in the pig-to-baboon kidney xenotransplantation model","volume":"23","author":"Hansen-Estruch","year":"2023","journal-title":"Am J Transplant."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0095","doi-asserted-by":"crossref","first-page":"11093","DOI":"10.1021\/acs.chemrev.0c00145","article-title":"Solid organ bioprinting: strategies to achieve organ function","volume":"120","author":"Jorgensen","year":"2020","journal-title":"Chem Rev."},{"issue":"Suppl","key":"10.1016\/j.semnephrol.2026.151689_bib0096","first-page":"S117","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","year":"2024","journal-title":"Kidney Int."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0097","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jama.2011.451","article-title":"A predictive model for progression of chronic kidney disease to kidney failure","volume":"305","author":"Tangri","year":"2011","journal-title":"JAMA."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0098","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ajkd.2021.08.024","article-title":"Approach to kidney biopsy: core curriculum 2022","volume":"80","author":"Najafian","year":"2022","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0099","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2023.11783","article-title":"Banff Digital Pathology Working Group: image bank, artificial intelligence algorithm, and challenge trial developments","volume":"36","author":"Farris","year":"2023","journal-title":"Transpl Int."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0100","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1001\/jama.2017.4046","article-title":"Assessment of global kidney health care status","volume":"317","author":"Bello","year":"2017","journal-title":"JAMA."},{"key":"10.1016\/j.semnephrol.2026.151689_bib0101","series-title":"The selection and use of essential medicines: WHO model list of essential medicines, 24th list","year":"2025"},{"key":"10.1016\/j.semnephrol.2026.151689_bib0102","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/01.mnh.0000444822.25991.f6","article-title":"Disparities in the burden, outcomes, and care of chronic kidney disease","volume":"23","author":"Crews","year":"2014","journal-title":"Curr Opin Nephrol Hypertens."}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929526000252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929526000252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:44:45Z","timestamp":1791924285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929526000252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":102,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0270929526000252"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2026.151689","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Options for Kidney Protection: Are Renin\u2013Angiotensin System Inhibitors Still Relevant?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2026.151689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151689"}}